Vital Therapies (VTL) Getting Somewhat Positive Media Coverage, Analysis Finds

Media headlines about Vital Therapies (NASDAQ:VTL) have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Vital Therapies earned a news sentiment score of 0.03 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.4558001496265 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of equities analysts have weighed in on the stock. Zacks Investment Research cut shares of Vital Therapies from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. ValuEngine cut shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research report on Friday, November 17th. Raymond James Financial reaffirmed a “buy” rating on shares of Vital Therapies in a research report on Tuesday, December 5th. Finally, BidaskClub cut shares of Vital Therapies from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $6.00.

Shares of Vital Therapies (NASDAQ:VTL) traded down $0.15 on Friday, hitting $6.00. 149,281 shares of the stock traded hands, compared to its average volume of 178,264. The firm has a market capitalization of $259.58, a PE ratio of -4.44 and a beta of 5.12. Vital Therapies has a 1-year low of $2.25 and a 1-year high of $6.70.

Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings results on Wednesday, October 25th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.02. During the same quarter last year, the firm posted ($0.32) EPS. sell-side analysts predict that Vital Therapies will post -1.26 earnings per share for the current fiscal year.

In other news, Director Muneer A. Satter bought 50,000 shares of Vital Therapies stock in a transaction that occurred on Thursday, December 7th. The shares were purchased at an average price of $4.77 per share, with a total value of $238,500.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Muneer A. Satter bought 100,000 shares of Vital Therapies stock in a transaction that occurred on Wednesday, December 13th. The stock was purchased at an average cost of $5.48 per share, for a total transaction of $548,000.00. The disclosure for this purchase can be found here. Insiders have bought 300,000 shares of company stock worth $1,520,000 in the last three months. Corporate insiders own 32.60% of the company’s stock.

WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with's FREE daily email newsletter.

Leave a Reply